Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Natural Killer (NK) Cell Therapy Clinical Trials, Proprietary Technologies, Collaborations & Market Opportunity Insight 2025" has been added to ResearchAndMarkets.com's offering.
This report provides an in-depth analysis of therapeutic strategies utilizing natural killer (NK) cells, intentionally omitting methods involving antibody engagers designed to bind and activate these cells.
Cell therapies are experiencing significant advances, revolutionizing treatments across multiple disease domains. NK cell therapies, in particular, are of great interest due to their promising efficacy. These therapies, initially developed for cancer, are now progressing toward non-cancerous conditions, including autoimmune diseases. NK cells play an essential role in targeting tumors and infections, with ongoing research aiming to enhance their ability to combat detrimental cells. The field, though in early developmental stages, is expanding rapidly, supported by cutting-edge research and growing financial backing, signaling a substantial shift in healthcare strategies.
A significant development in NK cell therapies is the rise of interest in allogeneic NK cells, derived from healthy donors and available as mass-produced off-the-shelf treatments. This scalability is noteworthy and is being explored in both cancer and autoimmune diseases, illustrating their expanding application. For instance, Nkarta is making strides in the development of allogeneic NK cell therapies for autoimmune conditions like myasthenia gravis, showcasing potential for reshaping immunotherapy approaches for both cancer and autoimmune disorders. Simultaneously, companies are focusing on engineered NK cells targeting specific cancers. An example is SMT Bio's SMT-NK, under evaluation for biliary tract cancer, utilizing immune checkpoint inhibitors to bolster treatment effectiveness—marking a significant advance in NK-based combination therapies.
The surge in NK cell therapy advancement is buoyed by strong funding from private and governmental sources. In late 2024, Indapta Therapeutics secured US$ 22.5 million to propel the clinical advancement of its allogeneic NK cell therapy, IDP-023, targeting both cancer and autoimmune conditions. This financial influx is pivotal for continuing trial data generation, thereby broadening the exploration of NK cell therapy capabilities. Concurrently, the City University of Hong Kong received a grant to innovate CAR-NK cells for treating autoimmune juvenile dermatomyositis, underlining the escalating interest and investment in NK cell therapy beyond cancer into diverse immune-mediated ailments.
Collaborations between biotech firms and large pharmaceuticals are also enhancing clinical development. Indapta Therapeutics' partnership with Sanofi to merge IDP-023 with Sarclisa (isatuximab) in multiple myeloma treatment highlights the strategic integration of NK therapies with established regimes to enhance efficacy. By combining NK cells with existing therapeutics, these strategies aim to circumvent the limitations of monotherapies. Furthermore, the integration of breakthrough technologies, such as nanomaterials and gene editing, into NK therapy is improving targeting precision and clinical outcomes. For example, nanoparticles are enhancing NK cell stabilization and their tumor-targeting capability, presenting a novel pathway to elevating therapy efficacy.
In conclusion, the NK cell therapy market is poised for significant growth, driven by substantial investment and technological innovation. Emphasizing allogeneic NK cells for both cancer and autoimmune diseases marks a transformative trend in immunotherapy approaches. Strategic partnerships, cutting-edge technologies, and steady financial support are likely to hasten NK therapy advancement, reshaping treatment paradigms for numerous challenging diseases. With the emergence of clinical data, the NK cell therapy sector is set to become a key player in future precision medicine, offering novel, scalable solutions for conditions resistant to conventional treatment methodologies.
Report Highlights & Findings:
- Global & Regional Market Trends By Indication
- First NK Cell Therapy Approval Expected By 2028
- Number Of NK Cell Therapies In Clinical Trials: >180 Therapies
- Highest Phase For NK Cell Therapies Clinical Trials: Phase II/III
- NK Cell Therapies Granted Fast Track & Orphan Status: > 5 Therapies
- Global Natural Killer Cell Therapies Clinical Trials By Company, Indication & Phase
- Insight On Recent Partnerships, Collaborations & Licensing Agreements
- NK Cell Therapies Proprietary Technologies By Company
- Monotherapy & Combinational Treatment Strategies
Key Topics Covered:
1. Introduction to Natural Killer (NK) Cell Therapy
2. Mechanism Of Action of NK Cell Therapy
2.1 Cytotoxic Action Of NK Cells
2.2 Working Of NK Cell Therapy
2.3 NK Cell Therapies Approaches
2.3.1 CAR NK Cell Therapies
2.3.2 TCR NK Cell Therapies
3. Treatment Strategies For NK Cell Therapies
3.1 NK Cell Therapy As Monotherapy
3.2 NK Cell Therapy As Combinatorial Agent
4. Natural Killer (NK) Cell Therapy Research & Development Trends By Indication
4.1 Cancer
4.1.1 Hematological Cancers
4.1.2 Solid Cancers
4.2 Autoimmune & Inflammatory Disorders
4.3 Microbial Infections
4.4 Neurodegenerative Diseases
5. NK Cell Therapy Characteristics Enhancement Approaches
5.1 Use Of Nanotechnology
5.2 Modifications In CARs
5.3 Use Of CRISPR/Cas9 Gene Editing
6. Global Natural Killer Cell Therapies Clinical Trials Overview
6.1 By Country
6.2 By Indication
6.3 By Patient Segment
6.4 By Phase
6.5 By Priority Status
7. Global Natural Killer Cell Therapies Clinical Trials By Company, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Phase-0
7.4 Phase-I
7.5 Phase-I/II
7.6 Phase-II
7.7 Phase-II/III
8. NK Cell Based Therapy Proprietary Approaches & Technologies Insight
8.1 Overview
8.2 Proprietary Technologies By Company
9. Partnerships & Funding for NK Cell Therapies
9.1 Recent Partnerships, Collaborations & Licensing Agreements
9.2 Funding Deals By Companies
10. Investigational NK Cell Therapies With FDA Designations
10.1 FDA Fast Track Designation
10.2 FDA Orphan Drug Designation
10.3 Regenerative Medicine Advanced Therapy Designation
11. NK Cell Therapies Market Trends & Clinical Trials Outlook
11.1 Current Market Trends, Developments & Clinical Trials Assessment
11.2 Future Commercialization Opportunity
12. Competitive Landscape
12.1 Acepodia
12.2 Beijing JD Biotech
12.3 Cartherics
12.4 Catamaran Bio
12.5 Century Therapeutics
12.6 City of Hope National Medical Center
12.7 CRISPR Therapeutics
12.8 CytoImmune Therapeutics
12.9 Cytovia Therapeutics
12.10 Dragonfly Therapeutics
12.11 Editas Medicine
12.12 Fate Therapeutics
12.13 Gamida-Cell
12.14 GC Biopharma/GC Lab Cell
12.15 GICELL
12.16 Glycostem
12.17 HK inno.N
12.18 ImmunityBio
12.19 Karolinska Institute
12.20 Kiadis Pharma
12.21 Nkarta Therapeutics
12.22 NKGen Biotech
12.23 ONK Therapeutics
12.24 Sanofi
12.25 Senti Biosciences
12.26 Shoreline Biosciences
12.27 Sian Wuhan Medical Technology
12.28 Smart Immune
12.29 Sorrento Therapeutics
12.30 Therabest Korea
12.31 University of Texas M. D. Anderson Cancer Center
12.32 XNK Therapeutics
12.33 Zelluna Immunotherapy
For more information about this report visit https://www.researchandmarkets.com/r/vkthr9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
